COLUMBUS, Ohio – New research shows that the lungs become more inflammatory with age and that ibuprofen can lower that inflammation.

Azerbaijan is one of the 18 high priority countries for Tuberculosis (TB) Control in the WHO European Region and one of the 27 high MDR-TB high burden countries in the world. In 2012, Azerbaijan notified a total of 8140 TB cases, 2800 of them were estimated with MDR-TB.

On 3^rd October 2014, the TB Europe Coalition was invited by WHO Europe to represent civil society working on tuberculosis across the European region at the first meeting of the Advisory Committee for the development of the “Tuberculosis Action Plan for the WHO European Region, 2016-2020”.

07 October 2014 - Geneva, Switzerland - Three outstanding organizations have been shortlisted for the 2014 Kochon Prize. The theme for this year focused on innovators working with TB communities to reach the three million people who are missed every year.

The Association for Multidrug-Resistant TB Patients' Support (AMRTPS) and the Romanian Angel Appeal (RAA) Foundation have drafted language for a law to give TB patients in Romania a right to treatment, as well as social and psychological support.

Tuberculosis rates in the UK are still unacceptably high. Public Health England notes in its annual UK reportthat 7892 cases of tuberculosis were notified in 2013, a decrease from 8729 cases reported in 2012. However, the incidence of 12·3 cases per 100 000 is still among the highest in western European countries. Another sobering comparison is that the incidence in the UK is four times that of the USA.

Abstract

The Medicines Patent Pool (MPP) is seeking proposals from individuals and organisations to assess the feasibility of expanding the mandate of the MPP into tuberculosis (TB). The proposed timeframe for the provision of the consultancy services is 15^th November 2014 to 27^th February 2015.

Tokyo, Japan (October 1, 2014) – Daiichi Sankyo Company Limited (hereafter, Daiichi Sankyo) today announced that it and its domestic generic subsidiary, Daiichi Sankyo Espha Co., Ltd. (hereafter Daiichi Sankyo Espha), have submitted a supplemental New Drug Application (sNDA) in Japan for the synthetic broad-spectrum oral antibacterial agent Cravit® Tablets 250mg and 500mg, Granules 10% (generic name: Levofloxacin hemihydrate) and Levofloxacin Tablets 250mg DSEP and 500mg DSEP, Granules 10% DSEP^*1 for the treatment of pulmonary and other tuberculosis disorders.

We need your input. Please join us at an event designed to get your feedback on formulation, color, pill burden, and other preferences for tomorrow’s TB drug regimens.